Great Point Partners
Great Point Partners is a private equity firm based in Greenwich, Connecticut, established in 2003. The firm focuses on special situation, buyout, and growth equity investments in healthcare companies across the United States, Canada, and Western Europe. Its investment strategy emphasizes sectors such as pharmaceutical infrastructure services, medical devices, and healthcare information technology-enabled services. Great Point Partners leverages the expertise of its CEO Advisory Board and Medical Advisory Board to provide guidance and support to the executives of its portfolio companies, fostering the development and success of innovative healthcare enterprises.
Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating and commercializing innovative treatments for diabetes. The company specializes in applying its proprietary formulation technologies to enhance existing drugs, primarily targeting rapid-acting mealtime insulin for patients with Type I and Type II diabetes through its product candidate, Linjeta. In addition to Linjeta, Biodel is exploring earlier-stage candidates, which include follow-on rapid-acting insulins, a sublingual tablet formulation of insulin known as VIAtab, a range of basal insulins, and a glucagon formulation. Through its proprietary VIAdel technology, Biodel studies the interactions between peptide hormones and small molecules to advance its product development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.